gpr 9

Anti-CXCR3/GPR9/CD183 Antibody is a potent monoclonal antibody targeting the chemokine receptor CXCR3, acting by competitively blocking the binding of pro-inflammatory chemokines (such as CXCL10) to the receptor's extracellular domain. The compound is an essential tool for investigating effector T cell recruitment, the pathogenesis of autoimmune diseases, and tumor immune microenvironment remodeling, aiming to inhibit excessive inflammatory cell infiltration by intervening in the CXCR3-mediated signaling axis.

GPR84antagonist 9 is an orally active GPR84 antagonist with an IC50 value of 0.012 μM. It can be utilized in research on inflammatory pain diseases.

NF-56-EJ40 hydrochloride is a potent, high-affinity, and highly selective human SUCNR1 (GPR91) antagonist with an IC50 of 25 nM and a Ki of 33 nM, and shows almost no activity towards rat SUCNR1. NF-56-EJ40 hydrochloride has high affinity for humanized rat SUCNR1 with a Ki value of 17.4 nM.

hGPR91 antagonist 1 is a potent and selective hGPR91 antagonist (IC50: 7 nM).

NF-56-EJ40 is an effective and highly selective antagonist of human SUCNR1 with an IC50 of 25 nM and a Ki of 33 nM.

hGPR91 antagonist 3 is an orally active, potent, and selective hGPR91 antagonist. hGPR91 antagonist 3 is used to study hypertension, autoimmune diseases, and retinal angiogenesis. hGPR91 antagonist 3 has been shown to be effective in the treatment of hypertension, autoimmune disease, and retinal angiogenesis.

Potent endogenous peptide agonist of Mas related GPR X2 (MRGPRX2, EC50 = 57.2 nM). Corresponds to amino acids 9 to 20 of proadrenomedullin.